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DNA Interstrand Cross-Links by H-pin Polyamide (S)-seco-CBI 
Conjugates 
Chuanxin Guo[a], Sefan Asamitsu[a], Gengo Kashiwazaki[a], Shinsuke Sato[b], Toshikazu Bando*, [a], Hiroshi 
Sugiyama*, [a], [b] 
Abstract: Although DNA interstrand cross-links (ICLs) agents are widely 
used as antitumor drugs, DNA sequence-specific ICLs agents are quite rare. 
In this study, H-pin imidazole–pyrrole polyamide 1-(chloromethyl)-2,3-
dihydro-1H-benzo[e]indol-5-ol (seco-CBI) conjugates that produce 
sequence-specific DNA ICLs have been designed and synthesized. 
Conjugates with H-pin polyamide and seco-CBI moieties were constructed 
for the recognition of a 7 bp DNA sequence and their reactivity and 
selectivity in DNA alkylation were evaluated by using high-resolution 
denaturing gel electrophoresis and sequence-specific plasmid cleavage. 
Conjugate 6, which contained a chiral (S)-seco-CBI, exhibited higher 
sequence-specific ICLs activity toward the target DNA sequence and was 
appropriately cytotoxic to a cancer cell line. Molecular modeling studies 
indicated that the higher activity of 6 results from the relative orientation of 
the cyclopropane group in the (S)-CBI unit. 
Use of DNA interstrand cross-linking (ICL) agents as a tool for 
antitumor therapy is based on their ability to inhibit both transcription 
and replication by preventing the separation of DNA strands.[1] 
However, it cannot be overlooked that there is a limitation in ICL 
antitumor drugs arising from side effect to untargeted normal cells. 
Tumor cells always share many common features with normal cells. 
Consequently, traditional ICL drugs cannot achieve selective toxicity 
to cancer cells.[2] Targeting oncogenes have contributed to the 
development of modern antitumor therapy.[3] The common theme in 
development of ICL drugs is to address the limitations in current 
chemotherapy and to design new drugs with mechanisms that are based 
on traditional agents.[4] For the goals of reducing side effect and 
increasing selectivity, many new types of cross-linking agents have 
been investigated extensively.[5] As a member of 
cyclopropapyrroloindole family, bizelesin (NSC-615291), a 
bifunctional alkylating agent that contains two alkylating CPIs linked 
by a flexible methylene chain.[6] Based on its preference for AT-rich 
sequence and antitumor activity,[7] the National Cancer Institute has 
selected bizelesin for potential chemotherapeutic agent.[8] Compared 
with the CPI, the seco-CBI moiety has greater reactivity and selectivity 
towards DNA and it is also more stable in aqueous solution.[9] The 
seco-CBI dimer was able to form DNA ICLs in cell nucleus and 
showed extreme cytotoxicity to cancer cell lines.[10] We conjugated the 
alkylation moieties with minor-groove-binding polyamides containing 
N-methylimidazole (Im) and N-methylpyrrole (Py), which uniquely 
recognize each of the four Watson–Crick base pairs[11] , and realized 
programmable sequence-specific DNA alkylation[12] and ICLs.[13] In 
this research, conjugates of H-pin type[14] Im-Py polyamide and 
enantiomeric or racemic seco-CBI were designed and synthesized. 
Both compounds target 5’-TGATTCA-3’ DNA sequence, and the CBI 
subunit efficiently alkylated two adenine sites to form an ICL at the 
predetermined DNA sequence. We also compared the efficiency of the 





  The synthetic steps to the H-pin type Im-Py polyamide (S)-seco-CBI 
conjugate were shown in Scheme 1. The H-pin type polyamide 
carboxylic acid 5, which was obtained through liquid-phase synthesis, 
was directly coupled with indole-(S)-seco-CBI alkylating subunits by 
using PyBOP as coupling agent.  Product conjugate 6 was purified by 
HPLC for use in DNA ICLs studies. By the same method, racemic type 
indole-seco-CBI was coupled with 5 to obtain the diastereomeric 
mixture 7. The (S)-seco-CBI[15] and racemic seco-CBI[16] were prepared 
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  To investigate whether the H-pin type polyamide indole-seco-CBI 
conjugates were able to form ICLs structure, a 40 bp dsDNA fragment 
containing the target sequence of 5’-TGATTCA-3’ was incubated with 
either 6 or 7 and then subjected to 15% denaturing polyacrylamide gel 
electrophoresis.[17] SYBR Green II staining was used to visualize the 
DNA fragments in the gel.  
  As shown in Figure 1, incubation of the DNA with conjugate 6 at 10 
nM (1 equiv), 50 nM (5 equiv) and 100 nM (10 equiv) provided 
prominent slower migrating band. According to previous reports, these 
bands were considered as DNA ICLs structure.[18] However for the 
conjugate 7, ICLs formation bands could only be observed at the 
highest concentration (100 nM, 10 equiv). Significantly low ICLs 
reactivity of 7 might be explained by the low content of 6. These 
results suggested that the conjugate 6 was able to form DNA ICLs 
structure effectively by alkylating the two adenines in opposite strands 
of DNA.  
Figure	1.	a)	The	DNA	sequences	of	the	forward	and	reverse	fragments.	b)	Alkylation	
induced	 ICLs	 of	 40	 bp	 dsDNA	 fragment	 (10	 nM)	 by	 conjugates	 6	 and	 7	 after	
incubation	 for	 18	 h	 at	 23	 °C.	 DNA	 and	 concentrations	 of	 the	 conjugates:	 Lane	 1	 =	






  To confirm the sequence specificity of ICLs against the target DNA 
sequence, DNA alkylating reaction was evaluated by using 5’-Texas 
Red labeled 197-bp forward/reverse DNA fragments and a DNA 
sequencer. The forward T7 strand contained the 5’-TGATTCA-3’ 
sequence, and the reverse SP6 strand contained the 5’-TGAATCA-3’ 
sequence. After the forward and reverse fragments respective 
incubated with 6 and 7, DNA alkylation sites were visualized by 
thermal cleavage and analyzed by denaturing polyacrylamide gel 
electrophoresis. Sanger sequencing was used to identify the alkylation 
sites.[12] 
  Figure 2 showed the DNA alkylation induced by conjugates 6 and 7 
on both strands. Attributed to high DNA sequence specificity of 
conjugate 6, the alkylation occurred predominantly at adenine sites in 
both the forward 5′-TGATTCA-3′ sequence and reverse 5′-
TGAATCA-3′ sequence. However, conjugate 7 provided very faint 
adenine site thermal cleavage bands on both strands. Higher ICLs 










conjugate	 7.	 The	 central	 schematic	 shows	 a	 representation	 of	 the	 recognition	 and	
alkylation	models	of	conjugates	6	and	7.	The	red	arrows	indicated	the	alkylation	sites	
that	were	inferred	from	sequencing	gel	analysis.  
  To further explore the sequence specificity of the H-pin type 
polyamide indole-seco-CBI conjugates, recombinant plasmid pGEM-T 
Easy/ICLs containing the ICLs target sequence was incubated with 6, 7, 
and hairpin Im/Py polyamide (S)-seco-CBI conjugate 8 (Figure S1), 
respectively. After incubation, the conjugates 6, 7 and 8 will bind at 
target sequences and alkylate adenine sites. Thermal treatment induced 
the recombinant plasmids cleavage at alkylation sites. DNA double-
strand or single-strand cleavage led to plasmid form changing. 
Different plasmid formations were separated by 1% agarose gel 
electrophoresis. As shown in Figure 3, conjugate 6’s bifunction 
alkylation and double-strands thermal cleavage led to the visualization 
of linear formation plasmid (Form III) in a concentration-dependent 
manner. However, conjugate 7 showed weaker double-strands thermal 
cleavage activity than conjugate 6. The conjugate 8 which induced 
mono-alkylation and single-strand cleavage at match sequence cannot 
produce Form III, the linear formation plasmid.[19] Importantly, the 
plasmid pGEM-T Easy/Control, without the target sequence, did not 
produced any Form III plasmid by conjugates 6.[20] These results 
demonstrated that conjugate 6 was superior to induce DNA sequence-
specific ICLs and undergo further double-strands cleavage at brief 
heating conditions. 
  To gain insight into the mechanism of alkylating reactivity of the H-
pin type Im/Py polyamide seco-CBI conjugates, molecular modeling 
studies of the target DNA fragment–conjugate complexes was carried 
out.[21] Alkylation of the adenine by seco-CBI occurred through the 
formation of a cyclopropane unit on the 1,2,9,9a-tetrahydrocyclopropa 
[1,2-c] benz [1,2-e] indol-4-one (CBI) moiety (Figure 4a). Conjugates 
9S and 9R were used for the molecular modeling studies. The two 
alkylation sites were indicated with red arrows in Figure 4b. As shown 
in Figure 4c, for complex 9S, the distance between the N3 atom of 
each adenine moiety and the C9 atom of the CBI cyclopropane unit 











structure in both legs of the H-pin polyamide retained a planar 
conformation, thereby allowing efficient binding to occur between the  
Figure	 3.	 a)	 Alkylation	 and	 thermal	 cleavage	 induced	 form	 change	 of	 recombinant	
plasmid	 pGEM-T	 Easy/ICLs	 (20	 nM)	 by	 conjugates	6,	7	 and	8.	 DNA	 and	 conjugates	







for	 6	 and	 8,	 and	 pGEM-T	 Easy	 Vector/Control	 containing	 match	 site	 for	 8.	 c)	
Schematic	representation	of	the	conjugate	6	recongnized	match	site	and	formed	ICLs.	
d)	 Schematic	 representation	 of	 the	 conjugate	 8	 recongized	 the	 match	 site	 and	
formed	mono-alkylation.	
polyamide and DNA. This planar conformation would also contribute 
to stabilizing the S-form CBI unit in the leading H-pin for efficient 
alkylation. Furthermore the angles of the N3-C9-C8b for the 9S were 
118° and 116°. Thus the cyclopropane rings were positioned in an 
efficient orientation for alkylation. However, for the R-form CBI unit, 
the cyclopropane ring was positioned on the opposite side, away from 
the DNA minor groove. In this case, the distances between the N3 
atom of the adenine moiety and the C9 atom of the CBI cyclopropane 
were 4.42 and 4.57 Å, respectively. These distances were considered 
too long to allow effective DNA alkylation to occur. Additionally the 
angles of the N3-C9-C8b for 9R were turn to inefficient orientation 
(62° and 77°) [10] Thus, the ICLs activity of conjugate 7, bearing the 
racemic form of seco-CBI moiety, was weaker than conjugates 6. 
For the demonstration of the biological property of 6 as an ICL agent, 
the cytotoxicity assay was performed against breast adenocarcinoma, 
MDA-MB-231. The results revealed that conjugate 6 (IC50 = 110 nM) 
showed higher cytotoxicity than 7 (IC50 = 1.5 µM), which is parallel 
with ICLs ability observed in Figures 1, 2 and 3. However, the 
cytotoxicity of hairpin 8 (IC50 = 21.2 nM) exhibited the highest 
cytotoxicity of the three kinds of conjugates (Figure S2). The reason 
why cytotoxicity of conjugate 6 weaker than 8 was unknown, however 
it might be attributed to the difference of cell permeability between H-
pin and hairpin. For comparison, ICL agents that are used as 
chemotherapeutic drugs, such as cisplatin, have a similar IC50 range 
(0.54 µM to 1.6 mM for cisplatin).[22]. 
 In summary, H-pin imidazole-pyrrole polyamide CBI conjugates 
have been designed and synthesized as sequence-specific ICLs agents. 
We have shown that the conjugate 6 can target a 7 bp DNA sequence, 
5′-TGATTCA-3′, with high reactivity and selectivity to form an ICL 
formation. Conjugate 6 had higher activity than 7 because of the chiral 
form of the seco-CBI moiety. Our findings suggested that alkylating H-
pin imidazole–pyrrole polyamide derivatives could be used to target 
specific gene sequences and form ICLs structure. These findings also 
provide the opportunity to develop a new generation of oncogene-
targeting ICLs chemotherapeutic drugs.[23] 	
Figure	 4.	 Molecular	 models	 of	 the	 target	 DNA–conjugate	 complex.	 a)	 H-pin	
polyamides	with	the	S-and	R-cyclopropane	CBI	derivatives,	9S	and	9R,	respectively.	b)	
Energy-minimized	 structure	 of	 the	 5ʹ-dGGTGATTCACC-3ʹ/5ʹ-dGGTGAATCACC-3ʹ-9S	
complex.	 The	 two	 alkylation	 sites	 were	 indicated	 with	 red	 arrows.	 The	 distance	
between	 the	 N3	 atom	 of	 the	 adenine	 moiety	 and	 the	 C9	 atom	 of	 the	 CBI	
cyclopropane	unit,	 the	angle	between	 the	N3,	C9	and	C8b	 in	 the	S-form	 (c)	 and	R-
form	(d)	of	CBI	were	measured.	Bottom	table	showed	the	distances	and	angles.		
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Experimental  Section  
 
General methods. Reagents and solvents were purchased from commercial suppliers and 
used without further purification. Solid-phase peptide synthesis was performed by using a 
PSSM-8 peptide synthesizer (Shimadzu, Kyoto). Water was purified with a Millipore Direct-Q 
(MQ) system. HPLC was performed with a Jasco PU-2089 HPLC pump, a UV-2075 HPLC 
UV/Vis detector, and either a Chemco-bond 5-ODS-H column (Chemco Scientific, 4.6 
mm×150 mm, 0.1% TFA in water/MeCN, flow rate: 1.0 ml/min, linear gradient elution of 0–
100% MeCN over 20 min, detection at 254nm) or a Chemcobond 5-ODS-H column (Chemco 
Scientific, 10 mm×150 mm, 0.1% TFA in water/MeCN, flow rate: 3.0 ml/min, linear gradient 
elution of 0–100% MeCN over 20 min, detection at 254 nm). TOF-MS (ESI) was performed on 
a BioTOF II (Bruker Daltonics) mass spectrometer in positive-ionization mode. UV spectra 
were recorded on a Nanodrop ND-1000 spectrophotometer. The DNA oligonucleotides and the 
5’-Texas-Red-labeled primers were purchased from Sigma-Aldrich. A GenElute plasmid mini 
prep kit and a Genelute PCR clean-up kit were purchased from Sigma-Aldrich. A Thermo 
Sequence core-sequencing kit was purchased from GE Healthcare. Polymerase chain reaction 
(PCR) was performed on an iCycler (Bio-Rad). Using a HITACHI SQ5500E DNA sequencer 
performed polyacrylamide gel electrophoresis and the data were analyzed by using FLAGLYS 
version 2 software (HITACHI). Denatured polyacrylamide electrophoresis gel was scanned by 
FLA-3000 (Fujifilm). NMR spectra were recorded on a JEOL JNM ECA-600 NMR 
spectrometer with tetramethylsilane as an internal standard. 1H NMR spectra (600 MHz) were 
recorded in parts per million (ppm) downfield of tetramethylsilane. The following abbreviations 
apply to spin multiplicity: s (singlet), d (doublet), t (triplet), q (quartet), qu (quintet), m 
(multiplet), and br (broad). NH2-indole-seco-CBI and NH2-indole-(S)-seco-CBI were 
synthesized according to a literature procedure.  
 
Synthesis of compound 2.  K2CO3 (0.350 g, 2.50 mmol), 1,6-dibromohexane (64 μl, 0.416 
mmol) were added to the DMF solution (2 mL) of compound 1 1 (200 mg, 0.832 mmol) and it 
was stirred vigorously at 40 °C for 66 h. The reaction mixture was filtered and the remaining 
solution was evaporated to remove DMF solvent. After adding cold water (100 mL) to the 
reaction mixture, the solid was filtered and dried under vacuum to obtain the crude product 2 
(198 mg, 0.352 mmol, yield 84%) as brown powder. Compound 2 was used in the next step 
without any further purification. 1H NMR (600 MHz, DMSO-d6): δ 9.11 (s, 2H; NH×2), 7.13 (s, 
2H; CH×2), 6.62 (s, 2H; CH×2), 4.18 (t, 4H, J = 7.2 Hz; CH2×2), 3.70 (s, 6H; CH3×2), 1.59 (m, 
4H; CH2×2), 1.43 (s, 18H; CH3×6), 1.24 (m, 4H; CH2×2). ESI-TOFMS: m/z calcd for C28H43N4O8+: 
563.3075 [M+H]+, found: 563.2790; HPLC : tR = 20.1 min (0.1% TFA/MeCN, linear gradient 
0-100 %, 0-20 min). 
 
Synthesis of compound 3.  Compound 2 (198 mg, 0.352 mmol) was dissolved in 4 N 
hydrochloric acid/ethyl acetate (2 mL) and the solution was stirred at rt for 30 min. After 
evaporation and drying under vacuum compound 3 was obtained as brown powder (124 mg, 
0.342 mmol, yield 98%). Compound 3 was used in the next step without any purification. 1H 
NMR (600 MHz, DMSO-d6): δ 9.98 (br, 4H; NH2×2), 7.30 (d, 2H, J = 1.4 Hz; CH×2), 6.81 (d, 
2H, J = 1.4 Hz; CH×2), 4.27 (t, 4H, J = 7.2 Hz; CH2×2), 3.75 (s, 6H; CH3×2), 1.63 (qu, 4H, J = 
6.5 Hz; CH2×2), 1.22 (m, 4H; CH2×2). ESI-TOFMS: m/z calcd for C18H27N4O4+: 363.2072 [M+H]+, 
found: 263.2014; HPLC: tR = 8.4 min (0.1% TFA/MeCN, linear gradient 0-100 %, 0-20 min). 
 
Synthesis of compound 4.  ImPyCO2H was synthesized following the previous paper.2 1H 
NMR (600 MHz, DMSO-d6); δ 12.18 (br, 1H; OH), 10.47 (s, 1H; NH), 7.47 (d, 1H, J = 1.4 Hz; 
CH), 7.38 (s, 1H; CH), 7.03 (s, 1H; CH), 6.98 (d, 1H, J = 2.0 Hz; CH), 3.98 (s, 3H; CH3), 3.82 (s, 
3H; CH3). A DMF solution (5 ml) of ImPyCO2H (169 mg, 0.684 mmol), DIEA (N, 
N-diisopropylethylamine) (474 μl, 2.74 mmol), PyBOP ((benzotriazol-1-yloxy) 
tripyrrolidinophosphonium hexafluorophosphate)  (353 mg, 0.684 mmol) and compound 3 
(124 mg 0.342 mmol) was stirred at 23 °C for 12 h, then the mixture was evaporated. After 
adding 0.1 N NaOH (120 ml) at 0 °C, the solvent was removed by filter to obtain compound 4 
(259 mg, 0.315 mmol, yield 92%) as a white powder. 1H NMR (600 MHz, DMSO-d6): δ 10.46 
(s, 2H; NH×2), 9.95 (s, 2H; NH×2), 7.50 (d, 2H, J = 1.4 Hz; CH×2), 7.39 (s, 2H; CH×2), 7.28 
(d, 2H, J = 2.0 Hz; CH×2), 7.18 (d, 2H, J = 2.0 Hz; CH×2), 7.04 (s, 2H; CH×2), 6.92 (d, 2H, J = 
2.0 Hz; CH×2), 4.24 (t, 4H, J = 7.6 Hz; CH2×2), 3.99 (s, 6H; CH3×2), 3.84 (s, 6H; CH3×2), 3.73 
(s, 6H; CH3×2), 2.61 (qu, 4H, J = 7.2 Hz; CH2×2), 1.26 (m, 4H; CH2×2). ESI-TOFMS: m/z calcd 
for C40H47N12O8+: 823.3634 [M+H]+, found: 823.3418; HPLC: tR= 12.8 min (0.1% TFA/MeCN, 
linear gradient 0-100%, 0-20 min). 
 
Synthesis of compound 5. Compound 4 (54 mg, 68 μmol) in 3 ml of THF : 2 M aq. NaOH 
(1 : 1), which was stirred at 40 °C for 48 h. After the reaction mixture was neutralized by acetic 
acid until pH = 6, the solvent was evaporated. The residue was suspended by 0.1 N HCl at 0 °C, 
then the solvent was removed by filter to obtain the crude and completely dried. Subsequently 
the solid was washed with a solution of MeOH : CH2Cl2 (1 : 1) (3 ml) then with THF (3 ml). 
Compound 5 (25.9 mg, 32.6 μmol, yield 48%) was collected as a gray solid, which was used in 
the next step without any purification. 1H NMR (600 MHz, DMSO-d6): δ 10.45 (s, 2H; NH×2), 
9.92 (s, 2H; NH×2), 7.45 (d, 2H, J = 2.3 Hz; CH×2), 7.39 (s, 2H; CH×2), 7.27 (d, 2H, J = 1.6 
Hz; CH×2), 7.17 (d, 2H, J = 2.1 Hz; CH×2), 7.04 (s, 2H; CH×2), 6.86 (d, 2H, J = 2.1 Hz; 
CH×2), 4.24 (t, 4H, J = 7.6 Hz; CH2×2), 3.99 (s, 6H; CH3×2), 3.84 (s, 6H; CH3×2), 2.61 (qu, 4H, 
J = 1.8 Hz; CH2×2), 2.38 (qu, 4H, J = 1.8 Hz; CH2×2). ESI-TOFMS: m/z calcd for C38H43N12O8+: 
795.3321 [M+H]+, found: 795.4049; HPLC: tR= 12.8 min (0.1% TFA/MeCN, linear gradient 
0-100%, 0-20 min). 
 
Synthesis of conjugates 6 and 7.  (S)-seco-CBI3 and NH2-indole-(S)-seco-CBI were 
synthesized by following previously reported procedure. A DMF solution (0.2 mL) of 
compound 5 (2.0 mg, 2.5 μmol), DIEA (2.5 μl, 15.1 μmol), PyBOP (5.2 mg, 10.0 μmol) was 
stirred at 23 °C for 30 min. After the formation of the activated 1-hydroxybenzotriazole ester 
was checked by analytical HPLC, NH2-indole-(S)-seco-CBI (3.0 mg, 7.6 μmol) was added to 
reaction vessel, and the reaction mixture was stirred at 23 °C for 10 h. Reaction solution was 
diluted by Et2O (1 mL), and the precipitate was collected by filtration and washed with Et2O (3 
mL) and CH2Cl2 (1 mL). The crude was purified by reverse-phase HPLC (0.1% TFA/ MeCN, 
linear gradient 55-80%, 0-20 min) to obtain conjugate 6 as a yellow solid (0.8 mg, 0.5 μmol, 
yield 21%). ESI-TOFMS: m/z calcd for C82H76Cl2N18O102+: 771.2679 [M+2H]2+, found: 771.2650; 
HPLC: tR= 28.5 min (0.1% TFA/MeCN, linear gradient 0-100%, 0-40 min). 
Similar synthetic procedure was used for the synthesis of conjugate 7 (0.5 mg, 0.3 μmol, yield 
10%). ESI-TOFMS: m/z calcd for C82H76Cl2N18O102+: 771.2679 [M+2H]2+, found: 771.2708; HPLC: 
tR= 28.5 min (0.1% TFA/MeCN, linear gradient 0-100%, 0-40 min). 
 
 




Hairpin Im-Py polyamide carboxylic acid was prepared in a stepwise method by using a 
previously reported Fmoc solid-phase procedure by using CLEAR Acid resin, Fmoc-Py-COOH, 
Fmoc-Im-COOH, Fmoc-PyIm-COOH, Fmoc-β-COOH, O-(1H-6-chlorobenzotriazole-1-yl)- 
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), DIEA and DMF. Cleavage from the 
CLEAR-Acid resin was performed with acidic conditions (950 µl TFA, 25 µl triisopropylsilane, 
25 µl H2O, rt, 30 min) (Wako). The corresponding crude samples were used as coupling 
partners with NH2-Indole-(S)-seco-CBI without further purification. (10.7mg, 12.1μmol, total 
54% yield, from 22.2 µmol of Im-CLEAR-Acid resin). 1H NMR (600 MHz, DMSO-d6): δ 10.40 
(d, 1H, J = 10.8 Hz; NH), 10.32 (d, 1H, J = 10.8 Hz; NH), 10.31 (d, 1H, J = 10.2 Hz; NH), 9.91 
(d, 1H, J = 10.8 Hz; NH), 9.61 (d, 1H, J = 10.2 Hz; NH), 9.33 (d, 1H, J = 10.2 Hz; NH), 10.40 
(d, 1H, J = 10.8 Hz; NH), 8.02 (br, 1H; NH), 7.62 (d, 1H; J = 11.4 Hz; CH), 7.58 (d, 1H; J = 
12.0 Hz; CH), 7.51 (m, 2H; CH×2), 7.49 (d, 1H; J = 10.8 Hz; CH), 7.16 (m, 2H; CH×2), 6.89 (d, 
1H; J = 9.6 Hz; CH), 4.01 (d, 3H; J = 11.4 Hz; CH3), 3.99 (d, 3H; J = 12.6 Hz; CH3), 3.94 (d, 
3H; J = 12.6 Hz; CH3), 3.93 (d, 3H; J = 11.4 Hz; CH3), 3.85 (d, 3H; J = 10.8 Hz; CH3), 3.80 (d, 
3H; J = 11.4 Hz; CH3), 3.18 (m, 2H; CH2), 2.36 (m, 2H; CH2), 2.03 (d, 3H; J = 11.4 Hz; CH3), 
1.78 (m, 2H; CH2), ESI-TOFMS: m/z calcd for C36H44N17O9+: 882.3502 [M+H]+, found: 
882.2945; HPLC: tR= 12.0 min (0.1% TFA/MeCN, linear gradient 0–100%, 0–20 min). 
Hairpin Im-Py polyamide carboxylic acid (2.0 mg, 2.3 µmol), DMF (200 µl), DIEA (2.3 µl, 13.6 
µmol), and PyBOP (3.5 mg, 6.8 µmol) were stirred for 30 min at rt. The formation of the 
activated 1-hydroxybenzotriazole ester was checked by analytical HPLC (tR= 14.3 min, 0.1% 
TFA/MeCN, linear gradient 0–100%, 0–20 min); then, NH2-indole-(S)-seco-CBI (2.7 mg, 6.8 
µmol) was added and the mixture was stirred overnight at rt. Et2O was added to the mixture and 
the precipitate was collected by centrifugation and washed with Et2O and CH2Cl2, followed by 
HPLC purification (0.1% TFA/MeCN, linear gradient 50–80 %, 0–20 min). After collecting the 
main peak fraction and lyophilization, conjugate 8 was obtained as a yellow solid (0.9 mg, 0.7 
µmol, 32% yield) ESI-TOFMS: m/z calcd for C60H61ClN20O102+: 628.2279 [M+2H]2+, found: 

















































































Denatured polyacrylamide gel electrophoresis.  10 nM 40 bp dsDNA fragment (5'- 
GAATTCGATTATCCGGTGATTCACCGGATAATCACTAGTG-3' / 
3'-CTTAAGCTAATAGGCCACTAAGTGGCCTATTAGTGATCAC-5') was incubated with 
various concentrations of H-pin type polyamide conjugates 10, 50, 100 nM in DMF with 5 mM 
sodium phosphate buffer (pH 7.0) at 23 °C for 18 h. After incubation, the reaction mixture was 
concentrated by using vacuum centrifugation. The pellet was dissolved in 5 μl formamide 
loading dye. A 2.0 μl aliquot was subjected to electrophoresis on a 15 % denaturing 
polyacrylamide gel with 6 M urea. The electrophoresis carried out at 4 °C for about 180 min. 
The gel was stained by SYBR Green II for 10 min and then scanned by FLA-3000 (Fujifilm). In 
order to analyze the data quantitively, the percentage of ICLs DNA bands were evaluated by 
Multi Gauge V3.1 (Fujifilm). For the lane 4, 5 and 6, the percentage of ICLs DNA bands were 
14%, 36% and 57% that formed by 6. For the lane 7, 8 and 9, the percentages of ICLs bands 
were 0, 9% and 16% that formed by 7. For the lanes 5 and 8, the ICLs ratio was 25% (9%/36%). 
For the lanes 6 and 9 the ratio was 28% (16%/57%). The values roughly correspond to expected 
yield. 
 
Preparation of pGEM-T Easy/ICLs. 
All of the oligonucleotides (5’-ATCCGGTGATTCACCGGATA-3’, 
5’-ATCCGGTGAATCACCGGAT-3’) were purchased from Sigma–Aldrich, annealed at a 
concentration of 10 μM, and ligated into the pGEM-T Easy vector (Promega). Escherichia coli 
JM109 competent cells (Promega) were transformed by the recombined plasmid and cultured on 
an LB plate with 100 μg/ml ampicillin, X-gal (32 μg, 20 mg/ml), and IPTG (25 μl, 100 mM) 
overnight at 37 °C. White colonies were identified by colony PCR in 20 μl of reaction mixtures 
that contained 250 nM of each primer (T7 primer, 5’-TAATACGACTCACTATAGGG-3’; SP6 
primer, 5’-TATTTAGGTGACACTATAG-3’), 200 μM dNTPs (Sigma Aldrich), 2 units of Taq 
polymerase, and ThermoPol reaction buffer (New England Bio Labs). Amplification of the 
DNA fragments was performed by incubating at 95 °C for 5 min, followed by 35 cycles at 95 
°C for 35 s, 50 °C for 35 s, 72 °C for 30 s, and a final extension step of 72 °C for 7 min. The 
appropriate colony was selected for transfer into LB medium (5 ml) with 100 mg/ml ampicillin 
and cultured overnight at 37 °C. The recombined plasmid pGEM-T Easy/ICLs was extracted by 
using a GenElute Plasmid Miniprep Kit (Sigma-Aldrich) and identified by using PCR (program 
and reaction mixtures were the same as above). 
 
Cloning of a 197 bp DNA fragment.  The forward T7 5’-Texas-Red-modified 197 bp DNA 
fragments was prepared by PCR with 5’-Texas Red-modified T7 primer (5’-Texas 
Red-TAATACGACTCACTATAGGG-3’) and SP6 primer 
(5’-TATTTAGGTGACACTATAGA-3’) from 1 μg/ml of the recombined plasmid pGEM-T 
Easy/ICLs. The reverse SP6 5’-Texas-Red-modified 197 bp DNA fragments was prepared by 
PCR with 5’-Texas Red-modified SP6 primer (5’-Texas 
Red-TATTTAGGTGACACTATAGA-3’) and T7 primer (5’- TAATACGACTCACTATAGGG 
-3’) from 1 μg/ml of the recombined plasmid pGEM-T Easy/ICLs. The 5’-Texas-Red-modified 
forward and reverse 197 bp DNA fragments purified by GenElute PCR Clean-up Kit (Sigma 
Aldrich) and their concentrations were determined by UV absorption. The sequence of forward 




ATGCATAGCTTGAGTATTCTATAGTGTCACCTAAATA-3’. The sequence of reverse SP6 






High-resolution gel electrophoresis.  The forward and reverse 197 bp DNA fragments (6 
nM) were alkylated by the polyamide conjugates at various concentrations from 62.5 nM to 250 
nM in DMF with 5 mM sodium phosphate buffer (pH 7.0) at 23 °C for 18 h. After incubation, 
the reaction mixture was quenched by calf thymus DNA and heated for 5 min at 95 °C. The 
solution was concentrated by using vacuum centrifugation. The pellet was dissolved in 7 μl of 
loading dye, heated at 95 °C for 20 min, and then immediately cooled to 0 °C. A 0.8 μl aliquot 
was subjected to electrophoresis on a 6% denaturing polyacrylamide gel by using a Hitachi 
SQ5500E DNA sequencer.  
 
Preparation of pGEM-T Easy/Control.  
The oligonucleotides (5’-GAATTCTTCTTCTGCTGTTGAATTCTTCTTCAGCAGTTA-3’, 
5’-AACTGCTGAAGAAGAATTCAACAGCAGAAGAAGAATTCA-3’) were purchased from 
Sigma–Aldrich, annealed at a concentration of 10 μM, and ligated into the pGEM-T Easy vector 
(Promega). Escherichia coli JM109 competent cells (Promega) were transformed by the plasmid 
and cultured on an LB plate with 100 μg/ml ampicillin, X-gal (32 μg, 20 mg/ml), and IPTG (25 
μl, 100 mM) overnight at 37 °C. White colonies were identified by colony PCR in 20 μl of 
reaction mixtures that contained 250 nM of each primer (T7 primer, 
5’-TAATACGACTCACTATAGGG-3’; SP6 primer, 5’-TATTTAGGTGACACTATAG-3’), 
200 μM dNTPs (Sigma Aldrich), 2 units of Taq polymerase, and ThermoPol reaction buffer 
(New England Bio Labs). Amplification of the DNA fragments was performed by incubating at 
95 °C for 5 min, followed by 35 cycles at 95 °C for 35 s, 50 °C for 35 s, 72 °C for 30 s, and a 
final extension step of 72 °C for 7 min. The appropriate colony was selected for transfer into LB 
medium (5 ml) with 100 mg/ml ampicillin and cultured overnight at 37 °C. The recombined 
plasmid pGEM-T Easy/Control was extracted by using a GenElute Plasmid Miniprep Kit 
(Sigma-Aldrich) and identified by using PCR (program and reaction mixtures were the same as 
above). 
 
Plasmid alkylation and thermal cleavage. 
20 nM pGEM-T Easy/ICLs was incubated with various concentrations of Im-Py polyamide 
seco-CBI conjugates (6, 7 and 8) 0, 20, 100, 200 nM in DMF with 5 mM sodium phosphate 
buffer (pH 7.0) at 23 °C for 24 h. 20 nM pGEM-T Easy/Control was incubated with 0 and 200 
nM conjugate 6 in DMF with 5 mM sodium phosphate buffer (pH 7.0) at 25 °C for 24 h. After 
incubation, the reaction mixture was heated at 90 °C for 15 min. Lane 1 was 20 nM pGEM-T 
Easy/ICLs plasmid without any treatment. Lane 13 was Pst I (TAKARA) single digested 20 nM 
pGEM-T Easy/ICLs plasmid, which used as linear form plasmid control. A 5.0 μl aliquot was 
subjected to electrophoresis on a 1% agarose gel. The electrophoresis carried out with 100 V at 
rt for about 45 min. The gel was stained by SYBR Green I for 20 min and then scanned by 
FLA-3000 (Fujifilm). 
 
Cell  culture and cytotoxicity assay. The human Caucasian breast adenocarcinoma 
MDA-MB-231 cell line was purchased from European collection of cell cultures. Cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 µg/ml streptomycin at 37°C in 5% CO2. 
Cytotoxicity assay using Cell Count Reagent SF were performed on 96-well plates. A 50 µl 
amount of each cell suspension was added at a density of 1 × 104 cells/well. Im-Py polyamide 
conjugates 6, 7 and 8 were dissolved in DMSO, and 50 µl of each solution in the medium (final 
DMSO concentration was 1%) was added. After treatment for 48 h, 10 µl of WST-8 reagent was 
added to each well and incubated at 37 °C. Absorbance was then measured at 450 and 600 nm 
using an MPR-A4i microplate reader (Tosoh). The results were shown at Figure S2. 
 
 
Figure	 S2.	 Cell	viability	assays	conducted	with	MDA-MB-231	cells	and	conjugates	a)	6,	 b)	7	 and	 c)	8.	Cells	were	treated	with	the	
conjugates	for	48	h.	The	data	are	means	±	SD	calculated	for	six	replicates	of	each	experimental	point.	
 
Molecular Modeling Studies.  Molecular modeling studies on the target DNA–conjugate 
complexes were conducted using previously reported method with small modfications.4 In brief, 
the starting B-form Watson-Crick DNA structure 
5’-dGGTGATTCACC-3’/5’-dGGTGAATCACC-3’ was constructed by the builder module 
with standard bond lengths and angles using Discovery Studio 4.5 program (BIOVIA). 
Conjugate 9S and 9R were manually inserted into the DNA minor groove of the target 
sequence 5’-dTGATTCA-3’/5’-dTGAATCA- 3’. Based on the polyamide-DNA recognition 
rules, the conjugate-DNA complexes were pre-minimized to maintain the interaction distance of 
hydrogen bonds between the polyamide part and DNA base pairs. For final minimization, the 
resulting complexes were solvated by explicit boundary model, and 5 mM of sodium cations 
and phosphate anions were placed in the system. The whole structures were then minimized to 
the stage where the RMS was less than 0.001 kcal/mol·Å by smart minimizer algorithm with 
harmonic restraints of the DNA. 
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